Literature DB >> 34035167

DLL1 orchestrates CD8+ T cells to induce long-term vascular normalization and tumor regression.

Naidong Zhang1, Rongping Yin2,3,4, Pei Zhou1, Xiaomei Liu1, Peng Fan1, Long Qian1, Li Dong1,3, Chenglin Zhang1,3, Xichen Zheng1, Shengming Deng1, Jiajie Kuai1, Zhenhua Liu1,5, Wen Jiang6, Xiaohua Wang7,4, Depei Wu8, Yuhui Huang9,10.   

Abstract

The immunosuppressive and hypoxic tumor microenvironment (TME) remains a major obstacle to impede cancer immunotherapy. Here, we showed that elevated levels of Delta-like 1 (DLL1) in the breast and lung TME induced long-term tumor vascular normalization to alleviate tumor hypoxia and promoted the accumulation of interferon γ (IFN-γ)-expressing CD8+ T cells and the polarization of M1-like macrophages. Moreover, increased DLL1 levels in the TME sensitized anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) treatment in its resistant tumors, resulting in tumor regression and prolonged survival. Mechanically, in vivo depletion of CD8+ T cells or host IFN-γ deficiency reversed tumor growth inhibition and abrogated DLL1-induced tumor vascular normalization without affecting DLL1-mediated macrophage polarization. Together, these results demonstrate that elevated DLL1 levels in the TME promote durable tumor vascular normalization in a CD8+ T cell- and IFN-γ-dependent manner and potentiate anti-CTLA4 therapy. Our findings unveil DLL1 as a potential target to persistently normalize the TME to facilitate cancer immunotherapy.

Entities:  

Keywords:  Delta-like 1; cancer immunotherapy; long-term tumor vascular normalization; tumor microenvironment

Mesh:

Substances:

Year:  2021        PMID: 34035167      PMCID: PMC8179177          DOI: 10.1073/pnas.2020057118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  61 in total

1.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

2.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.

Authors:  Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng
Journal:  N Engl J Med       Date:  2020-05-14       Impact factor: 91.245

3.  Immunological mechanisms of the antitumor effects of supplemental oxygenation.

Authors:  Stephen M Hatfield; Jorgen Kjaergaard; Dmitriy Lukashev; Taylor H Schreiber; Bryan Belikoff; Robert Abbott; Shalini Sethumadhavan; Phaethon Philbrook; Kami Ko; Ryan Cannici; Molly Thayer; Scott Rodig; Jeffrey L Kutok; Edwin K Jackson; Barry Karger; Eckhard R Podack; Akio Ohta; Michail V Sitkovsky
Journal:  Sci Transl Med       Date:  2015-03-04       Impact factor: 17.956

Review 4.  Molecular mechanisms and clinical applications of angiogenesis.

Authors:  Peter Carmeliet; Rakesh K Jain
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

5.  T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response.

Authors:  Michail V Sitkovsky
Journal:  Trends Immunol       Date:  2009-02-07       Impact factor: 16.687

6.  Inhibition of tumor angiogenesis and tumor growth by the DSL domain of human Delta-like 1 targeted to vascular endothelial cells.

Authors:  Xing-Cheng Zhao; Guo-Rui Dou; Li Wang; Liang Liang; Deng-Mei Tian; Xiu-Li Cao; Hong-Yan Qin; Chun-Mei Wang; Ping Zhang; Hua Han
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

7.  Benefits of vascular normalization are dose and time dependent--letter.

Authors:  Yuhui Huang; Triantafyllos Stylianopoulos; Dan G Duda; Dai Fukumura; Rakesh K Jain
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

Review 8.  Mini-review: overcoming tumor-intrinsic resistance to immune effector function.

Authors:  Ruth Ganss; Bernd Arnold; Günter J Hämmerling
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532

9.  An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.

Authors:  Asis Palazon; Petros A Tyrakis; David Macias; Pedro Veliça; Helene Rundqvist; Susan Fitzpatrick; Nikola Vojnovic; Anthony T Phan; Niklas Loman; Ingrid Hedenfalk; Thomas Hatschek; John Lövrot; Theodoros Foukakis; Ananda W Goldrath; Jonas Bergh; Randall S Johnson
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743

10.  Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Authors:  Tyler R Simpson; Fubin Li; Welby Montalvo-Ortiz; Manuel A Sepulveda; Katharina Bergerhoff; Frederick Arce; Claire Roddie; Jake Y Henry; Hideo Yagita; Jedd D Wolchok; Karl S Peggs; Jeffrey V Ravetch; James P Allison; Sergio A Quezada
Journal:  J Exp Med       Date:  2013-07-29       Impact factor: 14.307

View more
  10 in total

1.  An Immune-Related Long Noncoding RNA Pair as a New Biomarker to Predict the Prognosis of Patients in Breast Cancer.

Authors:  Hanwen Jiang; Jingxian Sun; Fucong Liu; Xincai Wu; Zhaohui Wen
Journal:  Front Genet       Date:  2022-06-22       Impact factor: 4.772

Review 2.  Co-Targeting Tumor Angiogenesis and Immunosuppressive Tumor Microenvironment: A Perspective in Ethnopharmacology.

Authors:  Jianbo Zhou; Li Wang; Cheng Peng; Fu Peng
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

3.  Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

Authors:  Teng He; Zhixing Hao; Mingjie Lin; Zhongwei Xin; Yongyuan Chen; Wei Ouyang; Qi Yang; Xiaoke Chen; Hui Zhou; Wanying Zhang; Pin Wu; Feng Xu
Journal:  Oncoimmunology       Date:  2022-07-01       Impact factor: 7.723

Review 4.  Hypoxia as a Modulator of Inflammation and Immune Response in Cancer.

Authors:  Rosa A Castillo-Rodríguez; Cristina Trejo-Solís; Alfredo Cabrera-Cano; Saúl Gómez-Manzo; Víctor Manuel Dávila-Borja
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

5.  Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.

Authors:  Caleb R Stoltzfus; Ramya Sivakumar; Leo Kunz; Brandy E Olin Pope; Elena Menietti; Dario Speziale; Roberto Adelfio; Marina Bacac; Sara Colombetti; Mario Perro; Michael Y Gerner
Journal:  Front Immunol       Date:  2021-08-05       Impact factor: 7.561

Review 6.  Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment.

Authors:  Vinicio Melo; Edwin Bremer; John D Martin
Journal:  Front Cell Dev Biol       Date:  2022-05-30

7.  Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy.

Authors:  Jian Ding; Yan Meng; Zelong Han; Xiaobei Luo; Xuxue Guo; Yiwen Li; Side Liu; Kangmin Zhuang
Journal:  Front Oncol       Date:  2022-05-16       Impact factor: 5.738

8.  Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.

Authors:  Yanhua Yue; Yang Cao; Xunyuan Mao; Fei Wang; Peng Fan; Long Qian; Shuxin Guo; Feng Li; Yanting Guo; Tongbing Chen; Yan Lin; Weimin Dong; Yue Liu; Yuhui Huang; Weiying Gu
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

9.  Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy.

Authors:  Peng Fan; Huiping Qiang; Zhenhua Liu; Qi Zhao; Ying Wang; Tingkun Liu; Xuan Wang; Tianqing Chu; Yuhui Huang; Wei Xu; Songbing Qin
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

10.  Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.

Authors:  Haiyan Xu; Ziwei Qi; Qi Zhao; Jiao Xue; Jiaxing Zhu; Yan He; Guirong Liu; Songbing Qin
Journal:  BMC Cancer       Date:  2022-08-25       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.